Precision BioSciences Inc. Stock News

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, to

Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter

Precision BioSciences has been on the candidate list for my Compounding Healthcare “Bio Boom” Portfolio. I am looking to find a spot for DTIL ahead of the ASH presentations. I intend to provide a

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene edi

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, to

PBCAR0191 is being explored in a phase 1/2 study in patients with relapsed/refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia. Data updates from PBCAR0191, PBCAR19B for non-H

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.

Which penny stocks are you watching right now? The post Looking For the Best Penny Stocks to Buy?

DTIL stock is advancing in early trading today after Precision BioScience announced a partnership with Novartis, a leading drug maker. The post Precision BioSciences (DTIL) Stock Treks Higher on Novar

Precision BioSciences Inc (NASDAQ: DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE: NVS)  P

Addex (ADXN) terminates the phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease. Shares fall.

BMO Capital Markets initiated the coverage on Precision BioSciences Inc (NASDAQ: DTIL) with an Outperform rating and a price target of $7. The analyst said the thesis is based on: The company's pr